Data/hora: 06/06/2024 00:28:58

Provedor de dados: 	56	
País: 	Brazil	
Título: 	Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies	
Autores: 	Kasmas,S.H.; Izar,M.C.; França,C.N.; Ramos,S.C.; Moreira,F.T.; Helfenstein,T.; Moreno,R.A.; Borges,N.C.; Figueiredo-Neto,A.M.; Fonseca,F.A.	
Data: 	2012-11-01	
Ano: 	2012	
Palavras-chave: 	Campesterol; Β-sitosterol; Desmosterol; Statin; Ezetimibe.	
Resumo: 	Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full benefits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A prospective, open label, randomized, parallel design study, with blinded endpoints, included 116 subjects. We compared the effects of a 12-week treatment with 40 mg rosuvastatin or the combination of 40 mg simvastatin/10 mg ezetimibe on markers of cholesterol absorption (campesterol and β-sitosterol), synthesis (desmosterol), and their ratios to cholesterol. Both therapies similarly decreased total and LDL cholesterol, triglycerides and apolipoprotein B, and increased apolipoprotein A1 (P &lt; 0.05 vs baseline for all). Simvastatin/ezetimibe increased plasma desmosterol (P = 0.012 vs baseline), and decreased campesterol and β-sitosterol (P &lt; 0.0001 vs baseline for both), with higher desmosterol (P = 0.007) and lower campesterol and β-sitosterol compared to rosuvastatin, (P &lt; 0.0001, for both). In addition, rosuvastatin increased the ratios of these markers to cholesterol (P &lt; 0.002 vs baseline for all), whereas simvastatin/ezetimibe significantly decreased the campesterol/cholesterol ratio (P = 0.008 vs baseline) and tripled the desmosterol/cholesterol ratio (P &lt; 0.0001 vs baseline). The campesterol/cholesterol and β-sitosterol/cholesterol ratios were lower, whereas the desmosterol/cholesterol ratio was higher in patients receiving simvastatin/ezetimibe (P &lt; 0.0001 vs rosuvastatin, for all). Pronounced differences in markers of cholesterol absorption and synthesis were observed between two equally effective lipid-lowering strategies.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012001100015	
Editor: 	Associação Brasileira de Divulgação Científica	
Relação: 	10.1590/S0100-879X2012007500118	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Medical and Biological Research  v.45 n.11 2012	
Fonte: 	info:eu-repo/semantics/openAccess